The U.S. FDA has granted orphan drug designation to LOXO-101 for the treatment of soft tissue sarcoma. LOXO-101 is an oral and selective inhibitor of tropomyosin receptor kinase (TRK) and is currently under development by Loxo Oncology, a biopharmaceutical company based in Stamford, CT. Soft tissue sarcomas are cancers of the soft tissues of the body, such as bone, muscle, fat, nerves, fibrous tissue, and blood vessels. There are many types of soft tissue sarcomas, and in most cases, the cause is unclear imposing a challenge to treat these patients. The TRK family has been implicated in many types of cancers including soft tissue sarcoma. LOXO-101 is currently in a Phase I trial for patients with advanced solid tumors who have progressed or are non-responsive to available therapies.